The state of GPCR research in 2004

Nature Reviews Drug Discovery

Volumn 3, Issue 7, 2004, Pages 575-626

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CELL SURFACE RECEPTOR; DRUG; G PROTEIN COUPLED RECEPTOR; HYBRID PROTEIN; LIGAND; MONOCLONAL ANTIBODY; PROTEIN SUBUNIT; RHODOPSIN;

BINDING SITE; BIOINFORMATICS; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CELL ASSAY; CRYSTAL STRUCTURE; DIMERIZATION; DISEASE ACTIVITY; DISEASE MODEL; DRUG DESIGN; DRUG RESEARCH; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ASSAY; FLUORESCENCE ANALYSIS; FLUORESCENCE CORRELATION SPECTROSCOPY; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUOROMETRY; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; MEDICAL EXPERT; MEDICAL RESEARCH; METHODOLOGY; MOLECULAR BIOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SPECTROSCOPY; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TECHNOLOGY; X RAY CRYSTALLOGRAPHY;

ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED; RESEARCH; TECHNOLOGY, PHARMACEUTICAL;

EID: 3543080493     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (224)

1. Decaillot, F. M. et al. Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation. Nature Struct. Biol. 10, 629-636 (2003).
2. Lembo, P. M. et al. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nature Neurosci. 5, 201-209 (2002).
3. Okada, T., Ernst, O. P., Palczewski, K. & Hofmann, K. P. Activation of rhodopsin: new insights from structural and biochemical studies. Trends Biochem. Sci. 26, 318-324 (2001).
4. Lu, Z. L., Saldanha, J. W. & Hulme, E. C. Seven-transmembrane receptors: crystals clarify. Trends Pharmacol. Sci. 23, 140-146 (2002).
5. Yamaguchi, T. Molecular constituents and phosphorylation-dependent regulation of the post-synaptic density. Mass Spec. Rev. 21, 266-286 (2002).
6. 1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416, 396-400 (2002).
7. 1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84-88 (2003).
8. 2 adrenergic receptor. J. Biol. Chem. 276, 24433-24436 (2001).
9. Janetopoulos, C., Jin, T. & Devreotes, P. Receptor-mediated activation of heterotrimeric G-proteins in living cells. Science 291, 2408-2411 (2001).
10. Vilardaga, J. P., Bunemann, M., Krasel, C., Castro, M. & Lohse, M. J. Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nature Biotechnol. 21, 807-812 (2003).
11. Yi, T. M., Kitano, H. &Simon, M. I. A quantitative characterization of the yeast heterotrimeric G protein cycle. Proc. Natl Acad. Sci. USA 100, 10764-10769 (2003).
12. Small, K. M., McGraw, D. W. & Liggett, S. B. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu. Rev. Pharmacol. Toxicol. 43, 381-411 (2003).
13. Tunaru, S. et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nature Med. 9, 352-355 (2003).
14. Matthes, H. W. et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature 383, 819-823 (1996).
15. Kieffer, B. L. Opoids: first lessons from knockout mice. Trends Pharmacol. Sci. 20, 19-26 (1999).
16. Roques, B. P., Daugé, V., Gacel, G. & Fournié-Zaluski, M. C. in Biological Psychiatry. Developments in Psychiatry Vol. 7 eds Shagass, C. et al.) 287-289 (Elsevier, New York, 1985).
17. Chang, K. J., Porreca, F. & Woods, J. H. The Delta Receptor (Marcel Dekker, New York, 2004).
18. Gether, U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21, 90-113 (2000).
19. Bockaert, J. et al. The 'magic tail' of G protein-coupled receptors: an anchorage for functional protein networks. FEBS Lett. 546, 65-72 (2003).
20. 2-adrenoceptor is essential for physiologic signaling and trafficking in cardiac myocytes. Proc. Natl Acad. Sci. USA 100, 10776-10781 (2003).
21. Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001).
22. Seifert, R., Wenzel-Seifert, K. & Kobilka, B. K. GPCR-Gα fusion proteins: molecular analysis of receptor-G-protein coupling. Trends Pharmacol. Sci. 20, 383-389 (1999).
23. Wenzel-Seifert, K., Hurt, C. M. & Seifert, R. High constitutive activity of the human formyl peptide receptor. J. Biol. Chem. 273, 24181-24189 (1998).
24. sα fusion protein. Eur. J. Biochem. 255, 369-382 (1998).
25. 1-receptor. J. Pharmacol. Exp. Ther. 305, 1104-1115 (2003).
26. 3. J. Biol. Chem. 274, 33259-33266 (1999).
27. q-proteins: limitations of Sf9 cells for the analysis of receptor/G-protein coupling. J. Neurochem. 80, 678-696 (2002).
28. Gille, A. & Seifert, R. 2′(3′)-O-(N-methylanthraniloyl)-substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors. J. Biol. Chem. 278, 12672-12679 (2003).
29. s-proteins. Naunyn-Schmiedeberg's Arch. Pharmacol. 368, 210-215 (2003).
30. Gille, A. et al. Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J. Biol. Chem. 279, 19955-19969 (2004).
31. Seifert, R., Wenzel-Seifert, K., Gether, U. & Koplika, B. K. Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. J. Pharmacol. Exp. Ther. 297, 1218-1226 (2001).
32. Furukawa, H. et al. Conformation of ligands bound to the muscarinic acetylcholine receptor. Mol. Pharmacol. 62, 778-787 (2002).
33. Luca, S. et al. The conformation of neurotensin bound to its G protein-coupled receptor. Proc. Natl Acad. Sci. USA 100, 10706-10711 (2003).
34. 4 binding to recombinant BLT1. J. Mol. Biol. 329, 815-829 (2003).
35. 2 adrenergic receptor: observation of conformational substates in a membrane protein. Proc. Natl Acad. Sci. USA, 98, 8469-9474 (2001).
36. Seifert, R. & Wenzel-Seifert, K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 366, 381-416 (2002).
37. s interactions: evidence for multiple receptor conformations. Mol. Pharmacol. 56, 348-358 (1999).
38. Steinberg, S. F. & Brunton, L. L. Compartmentation of G-protein-couded signaling pathways in cardiac myocytes. Annu. Rev. Pharmacol. Toxicol. 41, 751-773 (2001).
39. Luttrell, L. M. & Lefkowitz, R. J. The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell. Sci. 115, 455-465 (2002).
40. George, S. R., O'Dowd, B. F. & Lee, S. P. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nature Rev. Drug Discov. 1, 808-820 (2002).
41. Angers, S., Salahpour, A. & Bouvier, M. Dimenzation: an emerging concept for G protein-coupled receptor ontogeny and function. Annu. Rev. Pharmacol. Toxicol. 42, 409-435 (2002).
42. Bockaert, J. & Pin, J. P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 18, 1723-1729 (1999).
43. 3 receptors in vitro and in vivo. Proc. Natl Acad. Sci. USA 100, 11086-11091 (2003).
44. Leff, P., Scaramellini, C., Law, C. & McKechnie, K. A three-state receptor model of agonist action. Trends Pharmacol. Sci. 18, 355-362 (1997).
45. Kenakin, T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol. Sci. 24, 346-354 (2003).
46. Adan, R. A. H. & Kas, M. J. H. Inverse agonism gains weight. Trends Pharmacol. Sci. 24, 315-321 (2003).
47. 2 receptors. Proc. Natl Acad. Sci. USA 93, 6802-6807 (1996).
48. 1B adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J. Biol. Chem. 267, 1430-1433 (1992).
49. Chen, G. et al. Use of constitutive G-protein-coupled receptor activity for drug discovery. Mol. Pharmacol. 57, 125-134 (2000).
50. Menon, S. T., Han, M. & Sakmar, T. P. Rhodopsin: structural basis of molecular physiology. Physiol. Rev. 81, 1659-1688 (2001).
51. Sakmar, T. P., Manion, S. T., Marin, E. P. & Awad, E. S. Rhodopsin: insights from recent structural and mutagenesis studies. Annu. Rev. Biophys. Biomol. Struct. 31, 443-484 (2002).
52. 2 adrenoceptor. Kinetic evidence for intermediate conformational states. J. Biol. Chem. 279, 686-691 (2004).
53. Whistler, J. L., Chuang, H. H., Chu, P., Jan, L. Y. & von Zastrow, M. Functional dissociation of μ-opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23, 737-746 (1999).
54. 2A receptors in vitro and in vivo. Ann. NY Acad. Sci. 861, 121-127 (1998).
55. Seifert, R. & Wenzel-Seifert, K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Arch. Pharmacol. 366, 381-416 (2002).
56. Azzi, M. et al. β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl Acad. Sci. USA 100, 11406-11411 (2003).
57. 2 vasopressin receptor mutants. J. Clin. Invest. 105, 887-895 (2000).
58. 2-receptor with guanidine-type agonists. Mol. Pharmacol. 60, 1210-1225 (2001).
59. Palczewski, K. et al. Crystal structure of rhodopsin: a G protein-coupled receptor Science 289, 739-745 (2000).
60. Fotiadis, D. et al. Atomic-force microscopy: rhodopsin dimers in native disc membranes. Nature 421, 127-128 (2003).
61. Liang, X., Lu, Y., Wilkes, M., Neubert, T. A. & Resh, M. D. Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J. Biol. Chem. 278, 21655-21662 (2003).
62. 2 receptor. Mol. Pharmacol. 60, 373-381 (2001).
63. Ballesteros, J. A., Shi, L. & Javitch, J. A. Structural mimicry in G-protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 60, 1-19 (2001).
64. Filipek, S., Teller, D. C., Palczewski, K. & Stenkamp, R. The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors. Annu. Rev. Biophys. Biomol. Struct. 32, 375-397 (2003).
65. Malherbe, P. et al. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6(phenylethynyl)-pyridine. Mol. Pharmacol. 64, 823-832 (2003).
66. Bissantz, C., Bernard, P., Hilbert, M. & Rognan, D. Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets? Proteins 50, 5-25 (2003).
67. Tsamis, F. et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77, 5201-5208 (2003).
68. Archer, E., Maigret, B., Escrieut, C., Pradayrol, L. & Fourmy, D. Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors? Trends Pharmacol. Sci. 24, 36-40 (2003).
69. Allen, S., Rigby-Singleton, S. M., Harris, H., Davies, M. C. & O'Shea, P. Measuring and visualizing single molecular interactions in biology. Biochem. Soc. Transactions 31, 1052-1057 (2003).
70. MacKinnon, R. Potassium channels. FEBS Lett. 555, 62-65 (2003).
71. Dutzler, R., Campbell, E. B. & MacKinnon, R. Gating the selectivity filter in CIC chloride channels. Science 300, 108-112 (2003).
72. Bass, R. B. et al. The structures of BtuCD and MscS and their implications for transporter and channel function. FEBS Lett. 555, 111-115 (2003).
73. White, J. F., Trinh, L. B., Shiloach, J. & Grisshammer, R. Automated large-scale purification of a G-protein-coupled receptor for neurotensin. FEBS Lett. 564, 289-293 (2004).
74. Lundstrom, K. Semliki Forest virus vectors for rapid and high-level expression of integral membrane proteins. Biochim. Biophys. Acta 1610, 90-96 (2003).
75. Kobilka, B. K. Amino and carboxyl terminal modifications to facilitate the production and purification of a G protein-coupled receptor. Anal. Biochem. 231, 269-271 (1995).
76. 4 receptor BLT1 and the G-protein. J. Mol. Biol. 329, 801-814 (2003).
77. sα fusion protein. Proc. Natl Acad. Sci. USA 91, 8827-8831 (1994).
78. 1 receptor fused to β-arrestin displays a single-component, high-affinity molecular phenotype. Mol. Pharmacol. 62, 30-37 (2002).
79. Fernandez, C. & Wüthrich, K. NMR solution structure determination of membrane proteins reconstituted in detergent micelles. FEBS Lett. 555, 144-150 (2003).
80. 2 adrenergic receptor. Evidence for ligand-specific conformational changes. J. Biol. Chem. 270, 268-275 (1995).
81. Abramson, J. et al. Structure and mechanism of the lactose permease of Escherichia coli. Science 301, 610-615 (2003).
82. Palanche, T. et al. The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J. Biol. Chem. 276, 34853-34861 (2001).
83. Jordan, B. A. & Devi, L. A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399, 697-700 (1999).
84. Bowery, N. G. Mammalian γ-aminobutyric acid (B) receptors: structure and function. Pharmacol. Rev. 54, 247-264 (2002).
85. q-proteins. Mol. Pharmacol. 58, 954-966 (2000).
86. s-proteins. J. Biol. Chem. 277, 34434-34442 (2002).
87. Noble, F. & Roques, B. P. in Understanding G-Protein-Coupled Receptors and Their Pole in the CNS (eds Pangalos, M. & Davies, C.) 242-263 (Oxford Univ., Oxford, 2002).
88. B receptors - the first 7TM heterodimers. Trends Pharmacol. Sci. 20, 396-399 (1999).
89. Nelson, G. et al. Mammalian sweet taste receptors. Cell 106, 381-390 (2001).
90. Sexton, P. M., Albiston, A., Morris, M. & Tilakaratne, N. Receptor activity modifying proteins. Cell. Signal. 13, 73-83 (2001).
91. Ramsay, D., Kellett, E., McVey, M., Rees, S. & Milligan, G. Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochem. J. 365, 429-440 (2002).
92. 2-adrenergic receptor homo- and haterodimerization by bioluminescence resonance energy transfer. J. Biol. Chem. 277, 44925-44931 (2002).
93. 2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol. Endocrinol. 17, 677-691 (2003).
94. 1B-adrenergic receptors. J. Biol. Chem. 279, 15541-15549 (2004).
95. BR2. Nature 396, 676-679 (1998).
96. B receptor. Nature 396, 679-682 (1998).
97. Lee, S. P. et al. Dopamine D1 and D2 receptor coactivation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem. 24 May 2004 (doi: 10.1074/jbc.M401923200).
98. B-receptor subtypes assemble into functional heteromeric complexes. Nature 396, 683-687 (1998).
99. 2-dopamine receptor of the anterior pituitary gland. Mol. Pharmacol. 26, 214-227 (1984).
100. Park, P. S., Sum, C. S., Pawagi, A. B. & Wells, J. W. Cooperativity and oligomeric status of cardiac muscarinic cholinergic receptors. Biochemistry 41, 5588-5604 (2002).
101. Gripentrog, J. M. et al. Experimental evidence for lack of homodimerization of the G protein-coupled human N-formyl peptide receptor. J. Immunol. 171, 3187-3193 (2003).
102. Nelson, G. et al. An amino-acid taste receptor. Nature 416, 199-202 (2002).
103. He, L., Fong, J., von Zastrow, M. & Whistler, J. L. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomenzation. Cell 108, 271-282 (2002).
104. Kunishima, M. et al. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 407, 971-977 (2000).
105. Duthey, B. et al. A single subunit (GB2) is required for G-protein activation by the heterodimeric GABA(B) receptor. J. Biol. Chem. 277, 3236-3241 (2002).
106. Salahpour, A., Angers, S. & Bouvier, M. Functional significance of oligomerization of G-protein-coupled receptors. Trends Endocrinol. Metab. 11, 163-168 (2000).
107. Marshall, F. H. Heterodimenzation of G-protein-coupled receptors in the CNS. Curr. Opin. Pharmacol. 1, 40-44 (2001).
108. Wenzel-Seifert, K. & Seifert, R. Functional differences between human formyl peptide receptor isoforms 26, 98 and G6. Naunyn-Schmiedeberg's Arch. Pharmacol. 367, 509-515 (2003).
109. Horrobin, D. F. Modern biomedical research: an Internally self-consistent universe with little contact with medical reality? Nature Rev. Drug Discov. 2, 151-154 (2003).
110. McGavin, J. K. & Keating, G. M. Bisoprolol: a review of its use in chronic heart failure. Drugs 62, 2677-2696 (2002).
111. 1-receptor transgeric mice. Mol. Pharmacol. 60, 712-717 (2001).
112. Kvols, K. L. et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N. Engl. J. Med. 315, 663-666 (1986).
113. Katugampola, S. & Davenport, A. Emerging roles for orphan G-protein-coupled receptors in the cardiovascular system. Trends Pharmcol. Sci. 24, 30-35 (2003).
114. Wise, A., Gearing, K. & Rees, S. Target validation of G-protein coupled receptors. Drug Discov. Today 7, 235-246 (2002).
115. Roques, B. P. Novel approaches to targeting neuropeptide systems. Trends Pharmacol. Sci. 21, 475-483 (2000).
116. Strange, P. G. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol. Rev. 53, 119-133 (2001).
117. Gasparini, F., Kuhn, R. & Pin, J. P. Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. Curr. Opin. Pharmacol. 2, 43-49 (2002).
118. May, L. T. & Christopoulos, A. Allosteric modulators of G-protein-coupled receptors. Curr. Opin. Pharmacol. 3, 551-556 (2003).
119. Schaffhauser, H. et al. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol. Pharmacol. 64, 798-810 (2003).
120. sα has properties of a constitutively active receptor. J. Biol. Chem. 273, 5109-5116 (1998).
121. sα. J. Pharmacol. Exp. Ther. 299, 1013-1020 (2001).
122. sα proteins in Sf9 cells: limitations in comparison with fusion proteins. Biochim. Biophys. Acta 1613, 101-114 (2003).
123. Fischer, J. A., Muff, R. & Born, W. Functional relevance of G-protein-coupled-receptor-associated proteins, exemplified by receptor-activity-modifying proteins (RAMPs). Biochem. Soc. Trans. 30, 455-460 (2002).
124. Fujino, H. & Regan, J. W. Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer? Trends Pharmacol. Sci. 24, 335-340 (2003).
125. Brady, A. E. & Limbird, L. E. G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. Cell. Signal. 4, 297-309 (2002).
126. Mallee, J. J. et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J. Biol. Chem. 277, 14294-14298 (2002).
127. Morris, M., Christopoulos, A. & Sexton, P. M. RAMPs: 5 years on, where to now? Trends Pharmacol. Sci. 24, 596-601 (2003).
128. Ango, F. et al. Dendritic and axonal targeting of type 5 metabotropic glutamate receptor is regulated by Homer1 proteins and neuronal excitation. J. Neurosci. 20, 8710-8716(2000).
129. Tu, J. C. et al. Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron 21, 717-726 (1998).
130. Ango, F. et al. Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. Nature 411, 962-965 (2001).
131. Olson, W. C. et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol. 73, 4145-4155 (1999).
132. 2-adrenergic receptor. J. Biol. Chem. 278, 36740-36747 (2003).
133. Ogata, E. Parathyroid hormone-related protein as a potential target of therapy for cancer-associated morbidity. Cancer 88, 2909-2911 (2000).
134. Kakonen, S. M. & Mundy, G. R. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97 (Suppl. 3), 834-839 (2003).
135. Bowers, C. Y. Unnatural growth hormone-releasing peptide begets natural ghrelin. J. Clin. Endocrinol. Metab. 86, 1464-1469 (2001).
136. 2-adrenoceptor antibody behave as antagonists. Mol. Pharmacol. 58, 373-379 (2000).
137. Shigemoto, R., Abe, T., Nomura, S., Nakanishi, S. & Hirano, T. Antibodies inactivating mGluR1 metabotropic glutamate receptor block long-term depression in cultured Purkinje cells. Neuron 12, 1245-1255 (1994).
138. Sillevis Smitt, P. et al. Paraneoplastic cerebellar ataxia due to autoantilbodies against a glutamate receptor. New Engl. J. Med. 342, 21-27 (2000).
139. Orgiazzi, J., Madec, A. M. & Ducottet, X. The role of stimulating, function-blocking and growth-blocking anti-TSH receptor antibodies (TRAbs) in GD, Hashimoto's disease and in atrophic thyroiditis. Ann. Endocrinol. 64, 31-36 (2003).
140. Coffield, V. M., Jian, Q. & Su, L. A genetic approach to inactivating chemokine receptors using a modified viral protein. Nature Biotechnol. 21, 1321-1327 (2003).
141. Dillon, S. B., Verghese, M. W. & Snyderman, R. Signal transduction in cells following binding of chemoattractants to membrane receptors. Virchows Arch. B Cell. Pathol. Incl. Mol. Pathol. 55, 65-80 (1988).
142. i protein coupling in two formyl peptide receptor mutants associated with localized juvenile periodonttitis. J. Biol. Chem. 276, 42043-42049 (2001).
143. Seifert, R. &, Wenzel-Seifert, K. The human formyl peptide receptor as model system for constitutively active receptors. Life Sci. 73, 2263-2280 (2003).
144. 1-adrenergic receptor gene: developmental and cardiovascular effects. Proc. Natl Acad. Sci. USA 93, 7375-7380 (1996).
145. Roeske, W. R. & Wildenthal, K. Responsiveness to drugs and hormones in the murine model of cardiac ontogenesis. Pharmacol. Ther. 14, 55-66 (1981).
146. Murphy, P. M. Viral exploitation and subversion of the immune system through chemokine mimicry. Nature Immunol. 2, 116-122 (2001).
147. 5 receptor does not have a major effect on feeding in rats. Diabetes 51, 2441-2449 (2002).
148. Spiegel, A. M. Defects in G protein-coupled signal transduction in human disease. Annu. Rev. Physiol. 58, 143-170 (1996).
149. Inui, A. Neuropeptide gene polymorphisms and human behavioural disorders. Nature Rev. Drug Discov. 2, 986-998 (2003).
150. Brown, E. & MacLeod, R. J. Extracellular calcium sensing and extracellular calcium signalling. Physiol. Rev. 81, 239-297 (2001).
151. 2 vasopressin receptor unable to stimulate adenylyl cyclase. J. Biol. Chem. 268, 13030-13033 (1993).
152. 2+-sensing receptor gene mutation. Nature Genet. 8, 303-307 (1994).
153. Daub, H., Ulrich-Weiss, F., Wallasch, C. & Urrich, A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379, 557-560 (1996).
154. Prenzel, N. et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGE. Nature 402, 884-888 (1999).
155. Gutkind, J. S. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitrogen-activated protein kinase cascades. J. Biol. Chem. 273, 1839-1842 (1998).
156. Morello, J. P. & Bichet, D. G. Nephrogenic diabetes insipidus. Annu. Rev. Physiol. 63, 607-630 (2001).
157. Janovick, J. A., Maya-Nunez, G. & Conn, P. M. Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J. Clin. Endocrinol. Metab. 87, 3255-3262 (2002).
158. Illing, M. E., Rajan, R. S., Bence, N. F. & Kopito, R. R. A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. J. Biol. Chem. 277, 34150-34160 (2002).
159. Corvilain, B., Van Sande, J., Dumont, J. E. & Vassart, G. Somatic and germline mutations of the TSH receptor and thyroid diseases. Clin. Endocrinol. 55, 143-1158 (2001).
160. Sadée, W., Hoeg, E., Lucas, J. & Wang, D. Genetic variations in human G protein-coupled receptors: implications for drug therapy. AAPS PharmSci. 3, E22 (2001).
161. Chemelli, R. M. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437-451 (1999).
162. Lin, L. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365-376 (1999).
163. O'Rahilly, S. Leptin: defining its role in humans by the clinical study of genetic disorders. Nutr. Rev. 60, S30-S34 (2002).
164. Inui, A. Transgenic approach to the study of body weight regulation. Pharmacol. Rev. 52, 35-61 (2000).
165. Willie, J. T., Chemelli, R. M., Sinton, C. M. & Yanagisawa, M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu. Rev. Neurosci. 24, 429-458 (2001).
166. Hosoda, K. et al. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color mice. Cell 79, 1267-1276 (1994).
167. Gao, J. L., Lee, E. J. & Murphy, P. M. Impaired bacterial host defense in mice lacking the N-formylpeptide receptor. J. Exp. Med. 189, 657-662 (1999).
168. 2 receptor knockout mice in two animal models of learning and memory processing. J. Mol. Neurosci. 22, 159-166 (2004).
169. Arvanitakis, L., Geras-Raaka, E., Varma, A., Gershengorn, M. C. & Cesarman, E. Human herpesvirus KSHV encodes a constitutively active G-protain-coupled receptor linked to cell proliferation. Nature 385, 347-350 (1997).
170. Hunter, A. J., Nolan, P. M. & Brown, S. D. Towards new models of disease and physiology in the neurosciences: the role of induced and naturally occurring mutations. Hum. Mol. Genet. 9, 893-900 (2000).
171. Christopoulos, A. & Kenakin, T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54, 323-374 (2002).
172. Yanovski, S. Z. & Yanovski, J. A. Obesity. N. Engl. J. Med. 346, 591-602 (2002).
173. O'Dowd, B. et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136, 355-360 (1993).
174. Lee, D. K. et al. Discovery of a receptor related to the galanin receptors. FEBS Lett. 446, 103-107 (1999).
175. Quirion, R. & Weiss, A. S. Peptide E and other proenkephalin-derived peptides are potent κ opiate receptor agonists. Peptides 4, 445-449 (1983).
176. B receptor is required for activation and allosteric interaction between the subunits. J. Neurosci. 22, 7352-7361 (2002).
177. Vassilatis, D. K. et al. The G protein-coupled receptor repertoires of human and mouse. Proc. Natl Acad. Sci. USA 100, 4903-4908 (2003).
178. Fujisawa, Y. et al. Orphan GPCR ligands related to obesity. Curr. Med. Chem. Central Nervous System Agents 3, 101-120 (2003).
179. Wise, A., Jude, S. C. & Flees, S. The identification of ligands at orphan G-protein coupled receptors. Annu. Rev. Pharmacol. Toxicol. 44, 43-66 (2004).
180. Kojima, M. et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656-660 (1999).
181. Inui, A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nature Rev. Neurosci. 2, 551-560 (2001).
182. König, M. et al. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383, 535-538 (1996).
183. 4 receptors reveal substantial pharmacological species variation. J. Pharmacol. Exp. Ther. 299, 121-130 (2001).
184. 1-adrenergic receptor. J. Biol. Chem. 274, 12670-12674 (1999).
185. sα fusion proteins. Recept. Channels 9, 315-323 (2003).
186. Weinshilboum, R. Pharmacogenetics: the future is here! Mol. Interventions 3, 118-122 (2003).
187. Taghzouti, K. et al. Cognition enhancing effects in young and old rats of pBC264, a selective CCK-B receptor agonist. Psychopharmacol. 143, 141-149 (1999).
188. Neubig, R. R., Speeding, M., Kenakin, T. & Christopoulos, A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology. Pharmacol. Rev. 55, 597-606 (2003).
189. Kenakin, T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol. Pharmacol. 65, 2-11 (2004).
190. Milligan, G. & Bond, R. A. Inverse agonism and the regulation of receptor number. Trends Pharmacol. Sci. 18, 468-474 (1997).
191. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nature Rev. Drug Discov. 1, 198-210 (2002).
192. Kenakin, T. Efficacy at G-protein-coupled receptors. Nature Rev. Drug Discov. 1, 103-110 (2002).
193. 2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268, 4625-4636 (1993).
194. Weiss, J. M., Morgan. P. H., Lutz, M. W. & Kenakin, T. P. The cubic ternary complex receptor occupancy model. I. Model description. J. Theor. Biol. 178, 151-167 (1996).
195. Weiss, J. M., Morgan. P. H., Lutz, M. W. & Kenakin, T. P. The cubic ternary complex receptor-occupancy model. II. Understanding apparent affinity. J. Theor. Biol. 178, 169-182 (1996).
196. Weiss, J. M., Morgan. P. H., Lutz, M. W. & Kenakin, T. P. The cubic ternary complex receptor-occupancy model. III. Resurrecting efficacy. J. Theor. Biol. 178, 381-397 (1996).
197. 16 couple a wide variety of receptors to phospholipase C. J. Biol. Chem. 270, 15175-15180 (1995).
198. Milligan, G. & Rees, S. Chimaeric Gα proteins: their potential use in drug discovery. Trends Pharmacol. Sci. 20, 118-124 (1999).
199. Milligan, G. The use of receptor-G-protein fusion proteins for the study of ligand activity. Receptors Channels 8, 309-317 (2002).
200. Molinari P. et al. Promiscuous coupling at receptor-Gα fusion proteins. The receptor of one covalent complex interacts with the α-subunit of another. J. Biol. Chem. 278, 15778-15788 (2003).
201. Kraulis, P. J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. App. Crystall. 24, 946-950 (1991).
202. Merritt, E. A. & Bacon, D. J. Raster3D: Photorealistic molecular graphics. Methods. Enzymol. 277, 505-524 (1997).
203. Bouvier, M. Oligomerization of G-protein-coupled transmitter receptors. Nature Rev. Neurosci. 2, 274-286 (2001).
204. Arshavsky, V. Y., Lamb, T. D. & Pugh, E. N. Jr. G proteins and phototransduction. Annu. Rev. Physiol. 64, 153-187 (2002).
205. Blumer, J. R. & Lanier, S. M. Accessory proteins for G protein-signaling systems: activators of G protein signaling and other nonreceptor proteins influencing the activation state of G proteins. Receptor Channels 9, 195-120 (2003).
206. Clapham, D. E. & Neer, E. J. G protein β-subunits. Annu. Rev. Pharmacol. Toxicol. 37, 167-203 (1997).
207. Dolphin, A. C. G protein modulation of voltage-gated calcium channels. Pharmacol. Rev. 65, 607-627 (2003).
208. Gilman, A. G. G proteins and regulation of adenylyl cyclase. Biosci. Reports 15, 65-97 (1995).
209. Hofmann, F., Lacinova, L. & Klugbauer N. Voltage-dependent calcium channels: from structure to function. Rev. Physiol. Biochem. Pharmacol. 139, 33-87 (1999).
210. Hollinger, S. & Hepler, J. R. Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol. Rev. 54, 527-559 (2002).
211. Malbon, C. C. Insulin signalling: putting the 'G-' in protein-protein interactions. Biochem. J. 380, 11-12 (2004).
212. Nürnberg, B. & Ahnert-Hilger, G. Potential roles of heterotrimeric G proteins of the endomembrane system. FEBS Lett. 389, 61-65 (1996).
213. Nürnberg, B., Gudermann, T. & Schultz, G. Receptors and G proteins as primary components of transmembrane signal transduction. 2. G proteins: structure and function. J. Mol. Med. 73, 123-132 (1995).
214. Nürnberg, B. et al. Non-peptide G-protein activators as promising tools in cell biology and potential drug leads. Eur. J. Med. Chem. 34, 5-30 (1999).
215. Nürnberg, B. in Handbook of Experimental Pharmacology (Vol. 145) Bacterial Protein Toxins (eds Aktones, K. & Just, I.) 187-206 (Springer Verlag, Berlin, 2000).
216. Piekorz, R. & Nürnberg, B. Phospholipid kinases. X-Pharm [online] (2004).
217. Pitcher, J. A., Freedman, N. J. & Lefkowitz, R. J. G protain-coupled receptor kinases. Annu. Rev. Biochem. 67, 653-692 (1998).
218. Preininger, A. M. & Hamm, H. E. G protein signalling: insights from new structures. Science STIKE 3 Feb 2004 (doi: 10.1126/stke.2182004re3).
219. Rebecchi, M. J. & Pentyala S. N. Structure, function, and control of phosphoinositide-specific phospholipase C. Physiol. Rev. 80, 1291-1335 (2000).
220. Ronnett, G. V. & Moon, C. G proteins and olfactory signal transduction. Annu. Rev. Physiol. 64, 189-222 (2002).
221. Schwindinger, W. F. & Robishaw, J. D. Heterotrimeric G-protein βγ-dimers in growth and differentiation. Oncogene 20, 1653-1660 (2001).
222. Sunahara, R. K. & Taussig, R. Isoforms of mammalian adenylyl cyclase: multiplicities of signaling. Mol. Interv. 2, 168-184 (2002).
223. Spiegel, A. M. & Weinstein, L. S. Inherited diseases involving G proteins and G protein-couple receptors. Annu. Rev. Med. 55, 27-39 (2004).
224. Wettschureck, N., Mears, A. & Offermanns, S. Mouse models to study G-protein-mediated signaling. Pharmacol. Ther. 101, 75-89 (2004).